Recruiting
Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program
The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.
ClinicalTrials.gov IDNCT04652609
PhaseNA
Enrollment25
SponsorUniversidad de Granada
Age18 Years – 70 Years
SexFEMALE
Conditions studied
Breast Neoplasm
About this study
The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.
Interventions
- Other: PRESIONA — Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
Primary outcomes
- Patient-reported CIPN symptoms (Change from Baseline to 12 weeks (after intervention))
Eligibility information
Inclusion Criteria:
* 18 years or older
* HER2+ breast cancer diagnosis
* On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy)
Exclusion Criteria:
* Previous diagnosis of cancer
* Pregnant
* Cardiac pathology
* No symptoms or pathology that could be confused with neuropathy or related to diabetes
* No recommendation from oncologist for therapeutic exercise practice
Study locations
- University of Granada, Granada, 18016 Spain
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-16.